Yale researchers track the lifespan and myriad functions of mRNA
The findings could assist in achieving effective doses for new vaccines and help determine the biological roots of many cancers and diseases. (Source: Yale Science and Health News)
Source: Yale Science and Health News - January 19, 2022 Category: Universities & Medical Training Source Type: news

NCCN Endorses Full COVID - 19 Vaccination for Cancer Patients
The NCCN Advisory Committee supports the strong preference for mRNA vaccines and offers guidance on the timing of vaccination (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - January 14, 2022 Category: Cancer & Oncology Tags: Infections, Oncology, Pharmacy, Institutional, Source Type: news

NCCN Endorses Full COVID-19 Vaccination for Cancer Patients
FRIDAY, Jan. 14, 2022 -- Full COVID-19 vaccination, including third doses and/or boosters, is recommended for all patients with cancer, with a strong preference for mRNA vaccines, according to expert consensus recommendations published by the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 14, 2022 Category: Pharmaceuticals Source Type: news

AI can stratify risk of COVID-19 based on chest x-rays
An artificial intelligence (AI) algorithm could be utilized in low-resourc...Read more on AuntMinnie.comRelated Reading: States failed to prioritize cancer patients for COVID-19 vaccines AI model spots health disparities in COVID-19 patients Radiologists boost AI severity quantification of COVID-19 Strength in numbers: Federated learning boosts AI for COVID-19 AI could help diagnose TB in developing countries (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - January 14, 2022 Category: Radiology Source Type: news

Experts: mRNA vaccines can be used for cancer, heart problems, other maladies
Scientists have been working with mRNA technology for more than two decades, and many believe that it can produce vaccines against cancer, malaria, heart disease, HIV and other diseases. (Source: Health News - UPI.com)
Source: Health News - UPI.com - January 14, 2022 Category: Consumer Health News Source Type: news

HPV Vaccines Could Shift Rates of Many Cancers, Not Only Cervical HPV Vaccines Could Shift Rates of Many Cancers, Not Only Cervical
The impressive data on how HPV vaccination has cut cervical cancer rates tells only part of the story of how many other lives could be transformed.WebMD Health News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 13, 2022 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

The U.S. Is Facing Shortages in COVID-19 Drugs as Omicron Rages
Two brand-new COVID-19 pills that were supposed to be an important weapon against the pandemic in the U.S. are in short supply and have played little role in the fight against the Omicron wave of infections. The problem is that production is not yet at full strength and that the pill considered to be far superior, Pfizer’s, takes six to eight months to manufacture. While the supply is expected to improve dramatically in the coming months, doctors are clamoring for the pills now, not just because Omicron is causing an explosion of cases but because two antibody drugs that were once the go-to treatments don’t wor...
Source: TIME: Health - January 13, 2022 Category: Consumer Health News Authors: MATTHEW PERRONE/AP Tags: Uncategorized COVID-19 Drugs healthscienceclimate wire Source Type: news

Please be civilised to unvaccinated people like my son | Letter
We mustn ’t punish those who are fearful of getting the Covid vaccine, writes the mother of an autistic man who suffers from crippling anxietyI was disappointed by Dave Green ’s letter (12 January) regarding the penalties he suggests for those who are unvaccinated. I can empathise with his words as a previous cancer patient myself, and also as a frontline nurse, but I disagree with his judgment on “anti-vaxxers”. Those who have chosen not to have the vaccine do not all share the same mindset, and it is worth bearing this in mind before they are all excommunicated from society.My adult son is autisti...
Source: Guardian Unlimited Science - January 13, 2022 Category: Science Authors: Letters Tags: Vaccines and immunisation Health Coronavirus Infectious diseases Science Autism Source Type: news

HPV Vaccine Could Shift Rates of Non-Cervical Cancers
The impressive data on how HPV vaccination has cut cervical cancer rates tells only part of the story of how many other lives could be transformed. (Source: WebMD Health)
Source: WebMD Health - January 12, 2022 Category: Consumer Health News Source Type: news

South Africa: Health Urges People to Report Vaccine Adverse Events
[Govt of SA] The Department of Health has noted with concern a video clip circulating on social media platforms depicting a male patient suffering from what looks like a throat cancer, claiming this to be the result of a COVID-19 vaccine. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - January 12, 2022 Category: African Health Source Type: news

South Africa: Health Department Urges People to Report Vaccine Adverse Events
[Govt of SA] The Department of Health has noted with concern a video clip circulating on social media platforms depicting a male patient suffering from what looks like a throat cancer, claiming this to be the result of a COVID-19 vaccine. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - January 12, 2022 Category: African Health Source Type: news

At CES, Companies Make the Case That Telehealth Can Actually Work
During the COVID-19 pandemic, patients’ fears of getting infected in health care settings pushed many to use telehealth from the comfort of their own homes. That has come with some upsides. As telehealth has become more common, many providers and patients alike have appreciated the ease and convenience of doctors’ appointments from home, and it’s helped patients who have struggled to get access to healthcare—either because they live far from their provider, or due to a health condition that makes mobility difficult. But remote appointments have made certain kinds of care and monitoring more difficul...
Source: TIME: Health - January 11, 2022 Category: Consumer Health News Authors: Tara Law Tags: Uncategorized healthscienceclimate Technology Source Type: news

Ultrasound has tradeoffs for detecting skin cancer metastases
Ultrasound has higher sensitivity but also higher false-positive rates tha...Read more on AuntMinnie.comRelated Reading: Ultrasound jostles for bigger role in screening dense breasts Ultrasound best in margin assessment for breast surgery Should breast ultrasound scans after COVID vaccines be postponed? POCUS good for localizing catheters in newborn patients Routine ultrasound does not reduce hospital length of stay (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - January 11, 2022 Category: Radiology Source Type: news

Should breast ultrasound scans after COVID vaccines be postponed?
When using ultrasound to follow up on suspicious breast masses in patients wh...Read more on AuntMinnie.comRelated Reading: Ultrasound finds swollen glands on patients after COVID-19 vaccine Swollen glands from COVID vaccine more prevalent in breast imaging FDG-PET lymph node uptake after COVID-19 vaccines mimics cancer Adenopathy may occur after COVID-19 vaccination COVID-19 vaccine affects imaging results, researchers warn (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - January 6, 2022 Category: Radiology Source Type: news

CDC Director Rochelle Walensky Faces a Surging Virus —And a Crisis of Trust
If viruses know no borders, they
 have an equal disdain for human holidays. On Thanksgiving 2021, Dr. Rochelle Walensky shut off her phone for about 45 minutes and placed the turkey on the dining table to enjoy the holiday meal with her husband and three sons. When she turned the phone back on, she found, among the messages that had piled up, warnings that SARS-CoV-2 had morphed into a potentially dangerous new variant, identified in South Africa. Health officials there predicted that what would become known as the Omicron variant was much better at spreading than previous variants, and Walensky knew it was only a matter...
Source: TIME: Health - January 5, 2022 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 feature healthscienceclimate Magazine Source Type: news

Janssen Submits Biologics License Application to U.S. FDA Seeking Approval of Teclistamab for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
RARITAN, N.J., December 29, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking approval of teclistamab for the treatment of patients with relapsed or refractory (R/R) multiple myeloma. Teclistamab is an investigational, off-the-shelf, T-cell redirecting, bispecific antibody targeting both B-cell maturation antigen (BCMA) and CD3.“Despite all the gains that have been made in treating multiple myeloma, the unmet need still remains very high. Our relentless pursuit of tre...
Source: Johnson and Johnson - December 29, 2021 Category: Pharmaceuticals Tags: Latest News Source Type: news

Illness From Breakthrough COVID Often Severe for Cancer Patients Illness From Breakthrough COVID Often Severe for Cancer Patients
A mitigation approach that includes vaccination of close contacts, boosters, social distancing, and mask-wearing in public should be continued for the foreseeable future, according to a pre-proof.News Alerts (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 28, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news

Gaithersburg vaccine developer raises $21 million
Gaithersburg vaccine developer VLP Therapeutics Inc. has raised $21 million in a Series A-1 funding round, its second round this year, the company said in a press release Monday. The latest round will be used to accelerate research and development of a cancer treatment vaccine, the company said, in addition to preventative malaria and dengue vaccines. "We were fortunate enough to be able to raise funding in March to facilitate our cancer treatment vaccine R&D, ” Wataru Akahata, VLP's co-founder,… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - December 28, 2021 Category: Pharmaceuticals Authors: Ana Luc ía Murillo Source Type: news

Cancer Patients With Breakthrough COVID - 19 Remain at Risk for Severe Outcomes
No significant difference observed in 30 - day mortality for fully vaccinated versus unvaccinated cancer patients with COVID - 19 (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - December 27, 2021 Category: Cancer & Oncology Tags: Infections, Oncology, Critical Care, Journal, Source Type: news

' Breakthrough' COVID Infections Can Still Be Deadly for Cancer Patients
MONDAY, Dec 27, 2021 -- When fully vaccinated cancer patients develop a breakthrough case of COVID-19, most will become seriously ill and end up hospitalized, a new study finds. The conclusion stems from the experience of 54 cancer patients who... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - December 27, 2021 Category: General Medicine Source Type: news

Cancer Patients With Breakthrough COVID-19 Remain at Risk for Severe Outcomes
MONDAY, Dec. 27, 2021 -- Patients with cancer who develop breakthrough infection following COVID-19 vaccination remain at risk for severe outcomes, according to a study published online Dec. 24 in the Annals of Oncology. Andrew L. Schmidt, M.B.,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 27, 2021 Category: Pharmaceuticals Source Type: news

VLP Therapeutics raises $21M Series A-1 for cancer treatment vaccine, infectious diseases vaccine RandD
GAITHERSBURG, Md., Dec. 27, 2021 -- (Healthcare Sales & Marketing Network) -- US-based biotech company VLP Therapeutics, Inc. (VLPT) announced on December 27 that it has signed an agreement for an investment of US$21 million in a Series A-1 round from six... Biopharmaceuticals, Venture Capital VLP Therapeutics, vaccine (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 27, 2021 Category: Pharmaceuticals Source Type: news

HPV Vaccination Could Rid U.S. of Most Mouth, Throat Cancers in Men
(Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - December 23, 2021 Category: Cancer & Oncology Tags: Infections, Oncology, Pediatrics, Reproductive Medicine, News, Source Type: news

HPV Vaccination Could Rid U.S. of Most Mouth, Throat Cancers in Men
THURSDAY, Dec. 23, 2021 -- How do you prevent nearly 1 million cases of mouth and throat cancers in American men in this century? Find a way to reach an 80% HPV vaccination rate among adolescents, a new study suggests. HPV vaccination protects... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - December 23, 2021 Category: General Medicine Source Type: news

HPV Vaccination Could Rid U.S. of Most Mouth, Throat Cancers in Men
Title: HPV Vaccination Could Rid U.S. of Most Mouth, Throat Cancers in MenCategory: Health NewsCreated: 12/23/2021 12:00:00 AMLast Editorial Review: 12/23/2021 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - December 23, 2021 Category: Cancer & Oncology Source Type: news

FDA Approves Two New Indications for XARELTO ® (rivaroxaban) to Help Prevent and Treat Blood Clots in Pediatric Patients
RARITAN, NJ, Dec. 20, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved two pediatric indications for XARELTO® (rivaroxaban): the treatment of venous thromboembolism (VTE, or blood clots) and reduction in the risk of recurrent VTE in patients from birth to less than 18 years after at least five days of initial parenteral (injected or intravenous) anticoagulant treatment; and thromboprophylaxis (prevention of blood clots and blood-clot related events) in children aged two years and older with congenital heart disease w...
Source: Johnson and Johnson - December 21, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

COVID Vaccines Offer Only Some Protection for People With Myeloma
New research shows COVID-19 vaccines provide far less protection to people with multiple myeloma than to survivors of other types of cancer. (Source: WebMD Health)
Source: WebMD Health - December 15, 2021 Category: Consumer Health News Source Type: news

COVID Vaccines Offer Only Some Protection for People Battling Myeloma
WEDNESDAY, Dec. 15, 2021 -- COVID-19 vaccination provides far less protection to people with multiple myeloma than to survivors of other types of cancer, new research shows. The findings highlight the need for multiple myeloma patients“to be... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - December 15, 2021 Category: General Medicine Source Type: news

COVID Vaccines Offer Only Some Protection for People Battling Myeloma
Title: COVID Vaccines Offer Only Some Protection for People Battling MyelomaCategory: Health NewsCreated: 12/15/2021 12:00:00 AMLast Editorial Review: 12/15/2021 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - December 15, 2021 Category: Cancer & Oncology Source Type: news

Tanzania: Health Teams Tasked in Hpv Awareness Creation
[Daily News] COMMUNITY Health Management Teams (CHMT) in district councils have been advised to step up efforts in raising awareness among members of the public on the benefits of Human Papillomavirus Vaccines (HPV1&HPV2) in protecting girls under 15 against cervical cancer. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - December 14, 2021 Category: African Health Source Type: news

New Data from MajesTEC-1 Study Show Continued Deep and Durable Responses of Teclistamab (BCMAxCD3 Bispecific Antibody) in Treatment of Heavily Pretreated Patients with Multiple Myeloma
The objective responsive rate observed in this study suggests a potential benefit for many patients with triple-class exposed disease with an off-the-shelf therapy.”As of September 2021, 165 patients were treated with teclistamab at the SC 1.5 mg/kg dose across both Phase 1 and Phase 2 of MajesTEC-1.1 The primary objectives of the MajesTEC-1 Phase 1 study (NCT03145181) were to identify the recommended SC RP2D (part 1) and characterize the safety and tolerability of teclistamab at the RP2D (part 2). The primary objective of the MajesTEC-1 Phase 2 study (NCT04557098) was to evaluate the efficacy of teclistamab at the R...
Source: Johnson and Johnson - December 13, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Why More Kids Aren ’t Getting the HPV Vaccine
The human papillomavirus vaccine can prevent six potentially lethal malignancies, but inoculation is meeting with rising resistance from parents. (Source: NYT Health)
Source: NYT Health - December 13, 2021 Category: Consumer Health News Authors: Jane E. Brody Tags: Human Papillomavirus (HPV) Gardasil (Vaccine) Cervical Cancer Vaccination and Immunization Head and Neck Cancer Sexually Transmitted Diseases Parenting Teenagers and Adolescence Youth Cervarix (Vaccine) JAMA Pediatrics (Journal) Source Type: news

New Data from CARTITUDE-1 Study Show Continued Deep and Durable Responses of Ciltacabtagene Autoleucel (cilta-cel) in Treatment of Heavily Pretreated Patients with Multiple Myeloma
ATLANTA, Ga., December 12, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today longer-term results from the Phase 1b/2 CARTITUDE-1 study evaluating the efficacy and safety of ciltacabtagene autoleucel (cilta-cel), an investigational B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T-cell (CAR-T) therapy administered as a single infusion, in the treatment of patients with relapsed and/or refractory multiple myeloma. The data, featured as an oral presentation at the American Society of Hematology (ASH) 2021 Annual Meeting (Abstract #549) and selected as part of the Hi...
Source: Johnson and Johnson - December 12, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen Presents Updated Results Evaluating First-in-Class Talquetamab (GPRC5DxCD3 Bispecific Antibody) in Heavily Pretreated Patients with Multiple Myeloma
ATLANTA, Ga., December 11, 2021– The Janssen Pharmaceutical Companies of Johnson & Johnson announced today updated results from the MonumenTAL-1 Phase 1 first-in-human dose-escalation study of talquetamab (NCT03399799). Talquetamab is the only investigational off-the-shelf T cell redirecting bispecific antibody in clinical development targeting both GPRC5D, a novel multiple myeloma target, and CD3 on T cells.[1] Results from the study show that no new safety signals were observed with longer follow-up.1 Heavily pretreated patients with multiple myeloma treated with talquetamab at the recommended subcutaneous (SC)...
Source: Johnson and Johnson - December 11, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

New Clinical and Real-World Data Support Use of DARZALEX ® (daratumumab) in Patients with Newly Diagnosed Multiple Myeloma
ATLANTA, Ga., December 11, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today new analyses illustrating responses that first-line treatment with DARZALEX® (daratumumab)-based regimens may be able to achieve, including a potential survival benefit for DARZALEX® in combination with lenalidomide and dexamethasone (Rd). Updated data from the randomized Phase 2 GRIFFIN study in transplant-eligible patients and real-world evidence in transplant-ineligible patients were presented at the American Society of Hematology (ASH) 2021 Annual Meeting. Data from the GRIFFIN study will also b...
Source: Johnson and Johnson - December 11, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

New Data from Phase 3 GLOW Study Show Fixed-Duration Treatment with IMBRUVICA ® (ibrutinib) Plus Venetoclax Demonstrated Deeper and Sustained Undetectable Minimal Residual Disease Outcomes in First-Line Chronic Lymphocytic Leukemia
ATLANTA, Ga., December 11, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data from two studies evaluating the efficacy and safety of IMBRUVICA® (ibrutinib) plus venetoclax (I+V) as a potential fixed-duration treatment in adult patients with previously untreated chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). These data were both featured today during the American Society of Hematology (ASH) 2021 Annual Meeting. New secondary endpoint data from the Phase 3 GLOW study (NCT03462719) showed that fixed-duration treatment with I+V resulted in undetecta...
Source: Johnson and Johnson - December 11, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

A longer-lasting COVID vaccine? UCLA study points the way
FINDINGSResearchers at the  Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA have identified rare, naturally occurring T cells that are capable of targeting a protein found in SARS-CoV-2 and a range of other coronaviruses.The findings suggest that a component of this protein, called viral polymerase, could potentially be added to COVID-19 vaccines to create a longer-lasting immune response and increase protection against new variants of the virus.BACKGROUNDMost COVID-19 vaccines use part of the spike protein found on the surface of the virus to prompt the immune system to produc...
Source: UCLA Newsroom: Health Sciences - December 10, 2021 Category: Universities & Medical Training Source Type: news

Fear Keeps Some Cancer Patients From Getting COVID Vaccine
Title: Fear Keeps Some Cancer Patients From Getting COVID VaccineCategory: Health NewsCreated: 12/10/2021 12:00:00 AMLast Editorial Review: 12/10/2021 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - December 10, 2021 Category: Cancer & Oncology Source Type: news

Talk between immune cells could lead to new cancer vaccine
Yale scientists have helped identify crucial ways that immune system cells congregate and communicate with each other to identify and eradicate tumors. (Source: Yale Science and Health News)
Source: Yale Science and Health News - December 9, 2021 Category: Universities & Medical Training Source Type: news

Higher coronary artery calcium scores increase COVID-19 mortality risk
Patients with COVID-19 who have higher levels of coronary artery calcium fac...Read more on AuntMinnie.comRelated Reading: States failed to prioritize cancer patients for COVID-19 vaccines AI model spots health disparities in COVID-19 patients When it comes to PE, racial disparities exist among COVID-19 patients Chest CT gauges COVID-19 disease severity, mortality risk VR helps quantify lung damage in COVID-19 patients (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - December 9, 2021 Category: Radiology Source Type: news

What is the Difference Between a Paronychia and a Felon?
Discussion The hands are one of the most important parts of the body for interacting with the world. They are remarkably adapted having sensitive sensory receptors as well as feedback receptors for grasping, holding, and manipulating objects. Hands, especially with an opposable thumb, multiple joints within the hand, along with the wrist and elbow, allow the hand to move in multiple positions to manipulate the world. Hands also symbolize an emotional caring and sharing between individuals as hands are used to provide a true “human touch” in personal and social situations. Due to their important interactions in ...
Source: PediatricEducation.org - December 6, 2021 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news

Roche has rapidly developed additional testing options to differentiate mutations in the Omicron SARS-CoV-2 variant
Basel, 3 December 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) and TIB Molbiol, a newly acquired subsidiary within the Roche Diagnostics division, have added three additional Research Use Only (RUO) test kits for the detection of mutations present in the novel B.1.1.529 Omicron SARS-CoV-2 variant: VirSNip SARS Spike ins214EPE (RUO), VirSNiP SARS-CoV-2 Spike S371L S373P (RUO), VirSNip SARS Spike E484A (RUO). The World Health Organization (WHO) has classified the recently emerged SARS-CoV-2 variant, Omicron (B.1.1.529), as a COVID-19 variant of concern (VOC).The VirSNiP variant kits allow differentiation between unique mutation...
Source: Roche Investor Update - December 3, 2021 Category: Pharmaceuticals Source Type: news

Roche has rapidly developed additional testing options to differentiate mutations in the Omicron SARS-CoV-2 variant
Basel, 3 December 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) and TIB Molbiol, a newly acquired subsidiary within the Roche Diagnostics division, have added three additional Research Use Only (RUO) test kits for the detection of mutations present in the novel B.1.1.529 Omicron SARS-CoV-2 variant: VirSNip SARS Spike ins214EPE (RUO), VirSNiP SARS-CoV-2 Spike S371L S373P (RUO), VirSNip SARS Spike E484A (RUO). The World Health Organization (WHO) has classified the recently emerged SARS-CoV-2 variant, Omicron (B.1.1.529), as a COVID-19 variant of concern (VOC).The VirSNiP variant kits allow differentiation between unique mutation...
Source: Roche Media News - December 3, 2021 Category: Pharmaceuticals Source Type: news

Study: COVID-19 vaccines less effective in some cancer patients receiving chemotherapy, but better than nothing
COVID-19 vaccines offer less protection in people with cancer undergoing chemotherapy, but are still better than no protection at all, a study published Thursday by JAMA Oncology found. (Source: Health News - UPI.com)
Source: Health News - UPI.com - December 2, 2021 Category: Consumer Health News Source Type: news

Unvaccinated cancer patients 1.7 times as likely to contract Covid, 1.6 times higher risk of death
Researchers at the VA found that the COVID-19 vaccines are effective at preventing infection or death from the virus in cancer patients, even if the protection is not as strong as the general population. (Source: the Mail online | Health)
Source: the Mail online | Health - December 2, 2021 Category: Consumer Health News Source Type: news

States failed to prioritize cancer patients for COVID-19 vaccines
Most states winged it with poor results last spring when it came to prioritizin...Read more on AuntMinnie.comRelated Reading: Women benefit from scheduling mammograms around COVID vaccine Cardiac MRI assesses myocarditis after COVID-19 vaccination Is there a link between COVID-19 vaccines and myocarditis? FDG-PET lymph node uptake after COVID-19 vaccines mimics cancer PET imaging shows how COVID vaccines confound cancer detection (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - December 2, 2021 Category: Radiology Source Type: news

HPV Vaccine Is Reducing Cervical Cancers in Teens, Young Women
Title: HPV Vaccine Is Reducing Cervical Cancers in Teens, Young WomenCategory: Health NewsCreated: 11/30/2021 12:00:00 AMLast Editorial Review: 12/1/2021 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - December 1, 2021 Category: Cancer & Oncology Source Type: news

Tanzania: Send Your Daughters for Hpv Vaccination, Parents Urged
[Daily News] THE MINISTRY of Health, Community Development, Gender, Elderly and Children has urged parents to ensure that their daughters take the Human Papillomavirus Vaccine (HPV) to protect them from cervical cancer. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - December 1, 2021 Category: African Health Source Type: news

HPV Vaccine Has Protected Thousands Of People From Cervical Cancer, According To New Study
The HPV (human papillomavirus) vaccine pledged to help protect students between the ages of 12 and 13 from cervical cancer, among other cancers. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - December 1, 2021 Category: Pharmaceuticals Authors: Alice Broster, Contributor Tags: Healthcare /healthcare Innovation /innovation Source Type: news

Janssen Seeks Approval of IMBRUVICA ®(ibrutinib) in a Fixed-Duration Regimen for Patients with Untreated Chronic Lymphocytic Leukaemia (CLL)
BEERSE, BELGIUM, 30 November 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the submission of a Type II variation application to the European Medicines Agency (EMA) seeking approval of a new treatment option for IMBRUVICA® (ibrutinib) as a fixed-duration combination with venetoclax (I+V) for adult patients with previously untreated chronic lymphocytic leukaemia (CLL)."Ibrutinib was the first approved Bruton’s tyrosine kinase inhibitor and over the past seven years has become a key treatment for CLL and some other B-cell malignancies, treating more than 250,000 pati...
Source: Johnson and Johnson - November 30, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news